在青少年异常性关节炎中对甲甲酸的坚持进行了定性探索
Dori Abel1, Nellie Butler1, Anyun Chatterjee1
1The Children's Hospital of Philadelphia, 3401 Civic Center Boulevard, Philadelphia, PA 19104.
The Journal of pediatrics
|August 31, 2025
概括
鉴定青少年异常性关节炎 (JIA) 中甲状腺素 (MTX) 粘附的障碍物和促进因素是关键. 与患者相关的因素,如恶心和副作用,与药物特征一起,显著影响患者的服药,为更好的治疗策略提供信息.
科学领域:
- 儿童风湿病学
- 青少年的健康
- 药理学
背景情况:
- 青春期异常性关节炎 (JIA) 需要长期药物治疗.
- 甲托雷克萨特 (MTX) 是一种常见的JIA治疗方法,但坚持治疗可能很困难.
- 了解患者的观点对于改善患者的执法能力至关重要.
研究的目的:
- 在患有JIA的青少年中识别MTX坚持的障碍物和促进因素.
- 探索患者报告影响药物服药的因素.
- 为了更好地遵守MTX和提高生活质量.
主要方法:
- 定性横截面研究设计.
- 对20名被诊断患有JIA的青少年进行了半结构面试.
- 基于理论的分析,以确定世卫组织遵守领域内的主题.
主要成果:
- 常见的障碍包括预期的恶心,焦虑,繁忙的日程安排,副作用以及MTX的感觉特征 (颜色,味道,气味).
- 促进者包括患者的日常生活,提醒,家庭的支持,自主权,自动注射器,叶酸,积极的医疗保健经验和社区知识.
- 持有/不持有和口服/注射MTX使用者的平等代表性.
结论:
- 青少年对JIA的MTX的坚持受到患者,药物,医疗保健和社会经济因素的复杂相互作用的影响.
- 使用世卫组织的框架为坚持的挑战提供了有价值的见解.
- 这些发现可以指导开发有针对性的干预措施,以提高MTX的坚持和改善患者的结果.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
201
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
201
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
230
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
230


